Pfizer’s announcement that it will stop developing its oral weight-loss drug gave shares of Wegovy maker Novo Nordisk and ...

This week in Ozempic news: No more compounded GLP-1s, weight-loss pills are coming, and WeightWatchers is filing for ...

Many compounding pharmacies are no longer allowed to make cheaper versions of semaglutide and other GLP-1 drugs. A doctor ...

Eli Lilly ( LLY 0.89%) has been growing its sales at a good clip over the past year. This is partly thanks to Zepbound, a ...

A federal judge rejected a bid by compounding pharmacies to continue selling versions of weight-loss drug Wegovy and diabetes ...

In this edition of Daily Dose, Dr. Lacy Anderson answers a viewer's question about what discounts are available for weight ...

The pecking order of the obesity drug market is shifting. Eli Lilly , the $815 billion maker of blockbuster weight-loss drugs ...

As the FDA cracks down on compounded GLP-1 drugs like semaglutide and tirzepatide, the market for GLP-1 supplements is taking ...

BUFFALO, N.Y. — In January, Nicole Albanese, PharmD, clinical associate professor of pharmacy practice in the University at ...

The Columbia County Spring Fair is back in town, but this time with some policy changes amid disruptions last week.

The Lessie B. Price Center advertised their fitness programs for seniors and educational programs for youth at their open ...

Novo Nordisk scored a legal win against compounders of its blockbuster GLP-1 drugs. But it may not end the copycats.